A Novel Selective PPARα Agonist, CP900691, Improves Plasma Lipids, Lipoproteins, Glycemic Control and Reduces Body Weight in Diabetic Monkeys.Published in:Diabetes, 2007, v. 56, p. A138By:Flynn, Mickey;Shadoan, Melanie K.;Kavanagh, Kylie;Zhang, Li;Auerbach, Bruce J.;Harwood, H. J.;Wagner, Janice D.Publication type:Article